Help and Support
Emend, Ivemend, Proemend, fosaprepitant dimeglumine (MK-0517, ONO-7847)
Also known as: Emend For Injection
share with colleague
Merck & Co. Inc.
Injectable formulation of the selective neurokinin 1 (NK1) receptor antagonist
Neurokinin 1 (NK1) Substance P receptor (TACR1)
Mechanism of Action
Neurokinin-1 (NK-1) (Substance P) receptor antagonist
Latest Stage of Development
Prevent chemotherapy-induced nausea and vomiting (CINV); Prevent chemotherapy-induced nausea and vomiting (CINV) in cancer patients ages 6 months-17 years; Treat digestive symptoms resulting from the administration of antineoplastic agents.
Ono Pharmaceutical Co. Ltd.
Product Summary: Number of Indications in each Phase of Development by Disease Category
Archive Items are loading
Your California Privacy Rights
Use of Images
Create an Account
Help & Information Center
Copyright ©2014 BioCentury Publications, Inc. All Rights Reserved
Set Email Alert